AbbVie Inc. (ABBV)

65.97
1.55 2.30
NYSE : Health Technology
Prev Close 67.52
Open 67.28
Day Low/High 65.48 / 67.79
52 Wk Low/High 62.66 / 98.70
Volume 8.80M
Avg Volume 10.25M
Exchange NYSE
Shares Outstanding 1.48B
Market Cap 99.86B
EPS 3.70
P/E Ratio 24.04
Div & Yield 4.28 (6.28%)

Latest News

Cannabis Stocks Fall: Tilray Up 10.4%; General Cannabis Off 5.3%

Cannabis Stocks Fall: Tilray Up 10.4%; General Cannabis Off 5.3%

Tilray shares pop on first contract to deliver medical marijuana in Europe.

AbbVie Receives FDA Approval Of RINVOQ™ (upadacitinib), An Oral JAK Inhibitor For The Treatment Of Moderate To Severe Rheumatoid Arthritis

AbbVie Receives FDA Approval Of RINVOQ™ (upadacitinib), An Oral JAK Inhibitor For The Treatment Of Moderate To Severe Rheumatoid Arthritis

- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis[1-7]

Tesla Short-Sellers Are Up Some $3 Billion So Far in 2019

Tesla Short-Sellers Are Up Some $3 Billion So Far in 2019

That's the most successful short position so far this year.

AbbVie: The Right Mixture for the Perfect Stock

AbbVie: The Right Mixture for the Perfect Stock

ABBV has a positive earnings-per-share growth, an expanding price-to-earnings multiple and dividends that could result in annual shareholder returns well above 20%.

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

Dow Finished Up 300 Points, Rebound From Worst Day of the Year

The Dow ends up over 300 points on Tuesday, bouncing back one day after its worst session of the year so far.

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal

Allergan posted stronger-than-expected second quarter earnings Tuesday, and re-affirmed its full-year profit guidance, after the Botox maker agreed to a $63 billion takeover from biopharmaceutical group AbbVie in late June.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

AbbVie Submits New Drug Application To US FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

AbbVie Submits New Drug Application To US FDA For Investigational Elagolix For Management Of Heavy Menstrual Bleeding Associated With Uterine Fibroids In Women

- New Drug Application (NDA) is supported by data from pivotal Phase 3 studies of nearly 800 patients

Putting Amgen's Q2 Earnings Under the Microscope

Here we break down the numbers of some of the company's top drugs, but we now only have 175 shares remaining in this tag end of a position, as there are better health care stocks in the market right now.

Dollar Tree, Newmont Mining, AbbVie: 'Mad Money' Lightning Round

Dollar Tree, Newmont Mining, AbbVie: 'Mad Money' Lightning Round

Jim Cramer takes a look at Dollar Tree, Newmont Mining, AbbVie, Valley National Bancorp, Six Flags, DXC Technology, IBM and more.

Don't Fight the Fed: Cramer's 'Mad Money' Recap (Monday 7/29/19)

Don't Fight the Fed: Cramer's 'Mad Money' Recap (Monday 7/29/19)

Jim Cramer talks about what investors need to do ahead of an expected rate cut and amid earnings and trade upheaval.

AbbVie Rises on Strong Second-Quarter Results, Raised Guidance

AbbVie Rises on Strong Second-Quarter Results, Raised Guidance

Shares of drugmaker AbbVie gain after the company posts better-than-expected quarterly earnings and raises its guidance for the remainder of the year.

Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon

Draghi's End Game and a 3-Way Battle Shapes Up in the Cloud: Market Recon

Plus, Intel results crush expectations and Starbucks solidifies its comeback.

AbbVie Reports Second-Quarter 2019 Financial Results

AbbVie Reports Second-Quarter 2019 Financial Results

- Announced a Definitive Transaction Agreement to Acquire Allergan, Significantly Expanding and Diversifying AbbVie's Revenue Base with New Therapeutic Areas and Enhancing Long-Term R&D Funding Capacity to Allow for Continued Investment in Innovative Science

Amazon, Alphabet, McDonald's, Twitter and U.S. GDP - 5 Things You Must Know

Amazon, Alphabet, McDonald's, Twitter and U.S. GDP - 5 Things You Must Know

U.S. stock futures are rising following earnings reports from tech giants Amazon, Alphabet and Intel and as Wall Street looks ahead to the release of data on U.S. economic growth; Amazon falls after earnings miss forecasts; Alphabet jumps after an earnings beat and the parent of Google says it will buy back $25 billion of stock.

McDonald's, AbbVie, and Twitter - Earnings to Watch

McDonald's, AbbVie, and Twitter - Earnings to Watch

It's Fri-yay, July 26! From McDonald's to Twitter, here's what to watch.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

One Prescription for Uncertain Market? Gilead Sciences

One Prescription for Uncertain Market? Gilead Sciences

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Earnings Bonanza: Here's What Investors Should Expect in the Week Ahead

Earnings Bonanza: Here's What Investors Should Expect in the Week Ahead

It's a big week for tech earnings, watch the video to see which companies are reporting their quarterly earnings this week.

AbbVie Enhances Early Stage Oncology Pipeline With Acquisition Of Mavupharma

AbbVie Enhances Early Stage Oncology Pipeline With Acquisition Of Mavupharma

NORTH CHICAGO, Ill., July 15, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that it has acquired Seattle-based Mavupharma, a privately held biopharmaceutical company focused on novel approaches to target the STING (STimulator of INterferon...

AbbVie To Host Second-Quarter 2019 Earnings Conference Call

AbbVie To Host Second-Quarter 2019 Earnings Conference Call

NORTH CHICAGO, Ill., July 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2019 financial results on Friday, July 26 before the market opens.

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities In Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

It's Not Just the Fed: Cramer's 'Mad Money' Recap (Monday 7/8/19)

It's Not Just the Fed: Cramer's 'Mad Money' Recap (Monday 7/8/19)

Jim Cramer says investors may be misreading the Fed and the moment, but he's got your game plan for earnings season.

Starbucks, General Electric, AbbVie: 'Mad Money' Lightning Round

Starbucks, General Electric, AbbVie: 'Mad Money' Lightning Round

Jim Cramer checks in on Starbucks, General Electric, AbbVie, Adaptive Biotechnologies, Vector Group, PBF Energy and more.

Buyout Speculation Picks Up in Biotech

Buyout Speculation Picks Up in Biotech

Here's my take on the M&A landscape as well as my own speculation of some possible logical buyout targets.

What's the Difference Between Indica vs. Sativa?

What's the Difference Between Indica vs. Sativa?

Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 04/15/2019 settlement date, and AbbVie Inc is the #122 most shorted of the S&P 500 components, based on 5.57 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

My 3 Predictions for the Second Half of 2019

My 3 Predictions for the Second Half of 2019

Watch the Russell 2000, housing activity, and mergers and acquisitions.

TheStreet Quant Rating: B- (Buy)